Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 9/2018

01-09-2018 | Original Article

Impact of reconceptualization response shift on rating of quality of life over time among people with advanced cancer

Authors: Ala’ S. Aburub, B. Gagnon, S. Ahmed, A. M. Rodríguez, Nancy E. Mayo

Published in: Supportive Care in Cancer | Issue 9/2018

Login to get access

Abstract

Background

People with cancer may experience change in what constitutes quality of life (QOL) over time as a result of the cancer progression (true change) or adaptation to the experience, considered as a response shift phenomenon. As individualized measures are ideally suited to explore response shift, this study aimed to estimate the extent to which reconceptualization response shift occurred over time in a cancer population and the impact of this response shift on estimates of change on QOL measures.

Methods

Ninety-seven people with advanced cancer completed the study measures including the Patient-Generated Index (PGI) at diagnosis (T0) and 1 year later (T1). The response shift indicator was the change in the number of areas nominated (range − 4 to + 3). Multivariate linear regression was used to estimate the effect of changing areas on change in the PGI score, single indicators of global QOL, and the EQ-5Dindex adjusted for age and sex.

Results

Approximately 72% of people in this sample either added or dropped areas over time. People who dropped more than two areas had higher PGI scores at T1 than T0 while people who added areas showed low PGI score.

Conclusion

The results are consistent with the PGI framework as areas nominated tend to focus on negative aspects of QOL.
Literature
1.
Joly F, McAlpine J, Nout R, Åvall-Lundqvist E, Shash E, Friedlander M, Gynaecologic Cancer InterGroup (GCIG) (2014) Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action! Int J Gynecol Cancer 24(9):1693–1699CrossRefPubMed
2.
Heydarnejad MS, Hassanpour DA, Solati DK (2011) Factors affecting quality of life in cancer patients undergoing chemotherapy. Afr Health Sci 11(2):266–270PubMedPubMedCentral
3.
Helgesson O, Lissner L, Månsson J, Bengtsson C (2007) Quality of life in cancer survivors as observed in a population study of Swedish women. Scand J Prim Health Care 25(4):220–225CrossRefPubMedPubMedCentral
4.
Lindblad AK, Ring L, Glimelius B, Hansson MG (2002) Focus on the individual—quality of life assessments in oncology. Acta Oncol 41(6):507–516CrossRefPubMed
5.
Levine MN, Ganz PA (2002) Beyond the development of quality-of-life instruments: where do we go from here? J Clin Oncol 20(9):2215–2216CrossRefPubMed
6.
Patel KK, Veenstra DL, Patrick DL (2003) A review of selected patient-generated outcome measures and their application in clinical trials. Value Health 6(5):595–603CrossRefPubMed
7.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMed
8.
Cella D, Hernandez L, Bonomi AE, Corona M, Vaquero M, Shiomoto G, Baez L (1998) Spanish language translation and initial validation of the functional assessment of cancer therapy quality-of-life instrument. Med Care 36(9):1407–1418CrossRefPubMed
9.
Bowling A (1995) What things are important in people’s lives? A survey of the public’s judgements to inform scales of health related quality of life. Soc Sci Med 41(10):1447–1462CrossRefPubMed
10.
Soni MK, Cella D (2002) Quality of life and symptom measures in oncology: an overview. Am J Manag Care 8(18 Suppl):S560–S573PubMed
11.
Aburub AS, Mayo NE (2017) A review of the application, feasibility, and the psychometric properties of the individualized measures in cancer. Qual Life Res 26(5):1091–1104CrossRefPubMed
12.
Dabakuyo TS, Guillemin F, Conroy T, Velten M, Jolly D, Mercier M, Causeret S, Cuisenier J, Graesslin O, Gauthier M, Bonnetain F (2013) Response shift effects on measuring post-operative quality of life among breast cancer patients: a multicenter cohort study. Qual Life Res 22(1):1–11CrossRefPubMed
13.
Naus MJ, Ishler MD, Parrott CE, Kovacs SA (2009) Cancer survivor adaptation model: conceptualizing cancer as a chronic illness. J Clin Psychol 65(12):1350–1359CrossRefPubMed
14.
Sprangers MA, Schwartz CE (1999) Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 48(11):1507–1515CrossRefPubMed
15.
Schwartz CE, Rapkin BD (2004) Reconsidering the psychometrics of quality of life assessment in light of response shift and appraisal. Health Qual Life Outcomes 2:16CrossRefPubMedPubMedCentral
16.
Sprangers MA (1996) Response-shift bias: a challenge to the assessment of patients’ quality of life in cancer clinical trials. Cancer Treat Rev 22(Suppl A):55–62CrossRefPubMed
17.
Ahmed S, E. Mayo N, Wood-Dauphinee S, Hanley JA, Robin Cohen S (2004) Response shift influenced estimates of change in health-related quality of life poststroke. J Clin Epidemiol 57(6):561–570CrossRefPubMed
18.
Ubel PA, Peeters Y, Smith D (2010) Abandoning the language of “response shift”: a plea for conceptual clarity in distinguishing scale recalibration from true changes in quality of life. Qual Life Res 19(4):465–471CrossRefPubMed
19.
Barclay-Goddard R, Epstein JD, Mayo NE (2009) Response shift: a brief overview and proposed research priorities. Qual Life Res 18(3):335–346CrossRefPubMed
20.
Camilleri-Brennan J, Ruta DA, Steele RJ (2002) Patient generated index: new instrument for measuring quality of life in patients with rectal cancer. World J Surg 26(11):1354–1359CrossRefPubMed
21.
Tavernier SS, Beck SL, Clayton MF, Pett MA, Berry DL (2011) Validity of the Patient Generated Index as a quality-of-life measure in radiation oncology. Oncol Nurs Forum 38(3):319–329CrossRefPubMed
22.
Rodriguez AM, Mayo NE, Gagnon B (2013) Independent contributors to overall quality of life in people with advanced cancer. Br J Cancer 108(9):1790–1800CrossRefPubMed
23.
Aburub AS et al (2016) Using a personalized measure (Patient Generated Index (PGI)) to identify what matters to people with cancer. Support Care Cancer 24(1):437–445CrossRefPubMed
24.
Ruta DA, Garratt AM, Leng M, Russell IT, MacDonald L (1994) A new approach to the measurement of quality of life: the Patient-Generated Index. Med Care 32(11):1109–1126CrossRefPubMed
25.
Walters SJ, Brazier JE (2005) Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 14(6):1523–1532CrossRefPubMed
26.
Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed
27.
Cohen SR, Mount BM (2000) Living with cancer: “good” days and “bad” days—what produces them? Can the McGill quality of life questionnaire distinguish between them? Cancer 89(8):1854–1865CrossRefPubMed
28.
Cohen SR, Mount BM, Strobel MG, Bui F (1995) The McGill Quality of Life Questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 9(3):207–219CrossRefPubMed
29.
Cohen SR, Mount BM, Tomas JJN, Mount LF (1996) Existential well-being is an important determinant of quality of life. Evidence from the McGill quality of life questionnaire. Cancer 77(3):576–586CrossRefPubMed
30.
31.
Bansback N, Tsuchiya A, Brazier J, Anis A (2012) Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS One 7(2):e31115CrossRefPubMedPubMedCentral
32.
Oremus M, Tarride JE, Clayton N, Canadian Willingness-to-Pay Study Group, Raina P (2014) Health utility scores in Alzheimer’s disease: differences based on calculation with American and Canadian preference weights. Value Health 17(1):77–83CrossRefPubMed
33.
Shaw JW, Johnson JA, Coons SJ (2005) US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43(3):203–220CrossRefPubMed
34.
Poissant L, Mayo NE, Wood-Dauphinee S, Clarke AE (2003) The development and preliminary validation of a Preference-Based Stroke Index (PBSI). Health Qual Life Outcomes 1:43CrossRefPubMedPubMedCentral
35.
Arcuri JF, Borghi-Silva A, Labadessa IG, Sentanin AC, Candolo C, Pires di Lorenzo VA (2016) Validity and reliability of the 6-minute step test in healthy individuals: a cross-sectional study. Clin J Sport Med 26(1):69–75CrossRefPubMed
36.
Guerra-Balic M, Oviedo GR, Javierre C, Fortuño J, Barnet-López S, Niño O, Alamo J, Fernhall B (2015) Reliability and validity of the 6-min walk test in adults and seniors with intellectual disabilities. Res Dev Disabil 47:144–153CrossRefPubMed
37.
Schmidt K, Vogt L, Thiel C, Jäger E, Banzer W (2013) Validity of the six-minute walk test in cancer patients. Int J Sports Med 34(7):631–636CrossRefPubMed
38.
Middleton A, Fritz SL, Lusardi M (2015) Walking speed: the functional vital sign. J Aging Phys Act 23(2):314–322CrossRefPubMed
39.
Fritz S, Lusardi M (2009) White paper: “walking speed: the sixth vital sign”. J Geriatr Phys Ther 32(2):46–49CrossRefPubMed
40.
Martin F, Camfield L, Rodham K, Kliempt P, Ruta D (2007) Twelve years’ experience with the Patient Generated Index (PGI) of quality of life: a graded structured review. Qual Life Res 16(4):705–715CrossRefPubMed
41.
Cummins R (2000) Personal income and subjective well-being: a review. J Happiness Stud 1:133–158CrossRef
42.
Ahmed S, Mayo NE, Wood-Dauphinee S, Hanley JA, Cohen SR (2005) Using the patient generated index to evaluate response shift post-stroke. Qual Life Res 14(10):2247–2257CrossRefPubMed
43.
Howard GS, Dailey P (1979) Response-shift bias: a source of contamination of self-report measures. J Appl Psychol 64:144–150CrossRef
44.
Mayo NE, Aburub A’, Brouillette MJ, Kuspinar A, Moriello C, Rodriguez AM, Scott S (2017) In support of an individualized approach to assessing quality of life: comparison between Patient Generated Index and standardized measures across four health conditions. Qual Life Res 26(3):601–609CrossRefPubMed
Metadata
Title
Impact of reconceptualization response shift on rating of quality of life over time among people with advanced cancer
Authors
Ala’ S. Aburub
B. Gagnon
S. Ahmed
A. M. Rodríguez
Nancy E. Mayo
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4156-7

Other articles of this Issue 9/2018

Supportive Care in Cancer 9/2018 Go to the issue

Original Article

Investigation of the optimal duration of bed rest in the supine position to reduce complications after lumbar puncture combined with intrathecal chemotherapy: a multicenter prospective randomized controlled trial

Original Article

Assessment of psychological distress among Asian adolescents and young adults (AYA) cancer patients using the distress thermometer: a prospective, longitudinal study

Original Article

‘Being with’ or ‘doing for’? How the role of an end-of-life volunteer befriender can impact patient wellbeing: interviews from a multiple qualitative case study (ELSA)

Commentary

A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) clinic

Original Article

Bleeding frequency and characteristics among hematologic malignancy inpatient rehabilitation patients with severe thrombocytopenia

Original Article

A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits